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may be in close contact with the myocardium
is when the pericardium is closed, which we
routinely avoid when any grafts are put on
the coronary arteries.
It should also be remembered that the ap-
plied suction is 2816 cm H2O only at the
beginning of the drainage, with this decreas-
ing as the reservoir fills with blood.
I should like to clarify that I have a differ-
ent experience regarding the pain caused by
the removal of Redon drains. Even though I
remove them after disconnecting them from
the reservoir (some surgeons do not discon-
nect them), the maneuver is no less painful
than removing 32F chest tubes.
It is possible touse fewer drains in the peri-
cardial cavity, and someof the surgeons atmy
institution prefer to insert only two or three of
them. However, in my opinion the previously
proposed scheme of four drains covering all
regions around the heart is optimal.
I have recently changed the position of
the left pleural drain, inserting it through
the back wall of the pericardium rather than
through its lateral wall, as described in our
article. This is done so as to avoid the possi-
bility of phrenic nerve injury. It is mandatory
during this maneuver not only to lift the peri-
cardium but also to deflate the lungs, espe-
cially during off-pump surgery, to avoid
cautery lung injury.
The optimal negative pressure for our
drainage is still unclear, but 220 cm H2O
seems too low for drains with an inner diame-
ter of 2 mm. However, the main drawback of
the French drainage system is the substantial
additional cost caused by the use of a Pleur-
evac unit (Teleflex Inc, Research Triangle
Park, NC). The cost difference between using
five Redon drains with reservoirs (as we do)
and using three 32F chest tubes plus a Atrium
Oasis 3600 (AtriumMedicalCorp.,NH,USA)
reservoir is around $140 (US) per patient.
In summary, I would encourage our
French colleagues and other surgeons to re-
consider their drainage systems in favor of
the one presented in our article.
Marek Gwozdziewicz, MD, PhD
University Hospital Olomouc
Olomouc, Czech Republic
doi:10.1016/j.jtcvs.2008.03.024
Letters to the EditorRobotic cardiac surgery: Give it
more time!
To the Editor:
We read with great interest a recent editorial
by Dr Francis Robicsek regarding his per-ception that robotic cardiac surgery has es-
sentially been a failure.1 The data presented
are excellent and support the conclusion
that robotic cardiac surgery has not to date
been as widely adopted as some predicted.
His unrelenting assault on robotic cardiac
surgery does reflect the viewofmany cardiac
surgeons2 and must be seriously considered.
But is he correct in dismissing such a once-
promising technology so soon?
We too have had concerns about robotic
cardiac surgery: that it has been used by
many as a marketing tool, that a thoracotomy
is more painful than a sternotomy, that the
operations can be done more easily with en-
doscopic approaches, and that operative time
is increased. However, this all changed for
mewhen I had the privilege of being exposed
to the work of 2 incredibly talented master
surgeons, Dr Doug Murphy from Atlanta
and Dr Leland Siwek from Spokane, Wash-
ington. These surgeons have nearly perfected
the technique of totally endoscopic mitral
valve repair3 to the point at which if I needed
that operation today, I would have one of
them do it. Others have made major ad-
vances in revascularization procedures.4,5
What these and several other courageous sur-
geons have done is built world-class teams
around existing technology. The reason that
the rest of us have struggled with these cases
is hard to face: we have not been able to mus-
ter the same level of local support and team
building that is necessary to make the exist-
ing technology work. Many of us would
have little difficulty doing these procedures
if integrated into their programs.
Robotic cardiac surgery will eventually
prevail, just not on as rapid a timeline as
some might want. The da Vinci robot (Intu-
itive Surgical, Inc, Sunnyvale, Calif) was
only approved for cardiac surgery in 2002.
Are we to declare failure after only 6 years?
The new system is far improved over the
original, and the development of a robotic
atrial retractor and improved visualization
has made the procedures dramatically eas-
ier. We do need additional technologic
improvements, such as automated suturing
devices, tactile feedback, simpler anasto-
motic devices, an assistant surgeon console,
and better training. Most of the technology
needed to perfect robotic cardiac surgery al-
ready exists; it only needs to be integrated.
We must also recognize that every cardiac
surgery unit should not do robotic surgery.
Instead, highly specialized centers with ded-
icated teams and supportive environmentsThe Journal of Thoracic and Cardiovascuare already emerging. Surgeons uncomfort-
able with mitral repair or off-pump coronary
surgery through a sternotomy and those
without major institutional support should
stay away from the robot.
On a deeper level, we must recognize
that innovation must become the mantra
of this specialty for it to survive. One of
the reasons for the declining interest in
the specialty is a perception that we are
not innovating and therefore doomed to ex-
tinction. Endovascular innovation is being
recognized as something we must embrace.
I would add other minimally invasive ap-
proaches, such as robotics, to this effort.
Rather than throwing in the towel, we
should work to fix the current technical
limitations of robotic cardiac surgery just
as our predecessors tackled challenges of
similar difficulty in years past. We have
for too long lived off of their accomplish-
ments.
Ironically, the first cardiac surgery I saw
was in 1989 in the summer before medical
school. The surgeon was Dr Francis Robic-
sek. He was larger than life and commanded
unquestioned respect from everyone in the
hospital and clearly deserved it. This is
where my first interest in cardiac surgery
as a profession began. He and his partners
spoke of an exciting time in cardiac surgery
at which all sorts of new innovations were
occurring. I was hooked. Dr Robicsek, it is
time to revive that spirit, not kill it.
T. Sloane Guy, MD, MBAa,b
Elaine Tseng, MDa,b
Department of Surgerya
University of California
San Francisco Veterans Administration
Medicalb Center
San Francisco, Calif
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The proof is on you, gentlemen.
Francis Robicsek, MD, PhD
Carolinas Heart and Vascular Institute
University Heart Center
Hamburg, Germany
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I appreciate the earnest comments of my
colleagues.
Evidently, we see the potentials of tele-
robotics in a different perspective. They
believe not only that robotics is the future
of cardiac surgery, but also that the future
is already here! I respectfully disagree.
They kindly recall my role as an ‘‘inno-
vator.’’ With my 12 patents (the last one
in 2008), I would not deny it. However, I
was also the one who, as the invited discus-
sant to the first lecture of Andreas Gruntzig,
stated that coronary balloon angioplasty will
have an unacceptable recurrence rate, and I
also proved soon after its introduction that
aortic balloon valvuloplasty will be a disas-
ter. To be an innovator means not to
‘‘change’’ but to change toward the better.
In today’s era of evidence-based medi-
cine, the rules of innovation are strict. In-
formed consent is not a nebulous concept
anymore. The margins of clinic and industry
are better defined. Novel methods must un-
dergo intense scrutiny not only from a clini-
cal standpoint but also from an ethical and
economic aspect. Because results of telero-
botics might have reached, but certainly
did not exceed, those obtained with simpler
minimally invasive methods and because
telerobotics has definite marketing under-
tones, with its costs now exceeding a billion
dollars in equipment alone, we are obligated
to ask specific questions. In my editorial I
was asking these questions with an open
mind but also with a healthy dose of old-
fashioned skepticism.
The closing words of my editorial were
these:
Elements of robotics could indeed be
part of the future technology of mini-
mally invasive cardiac interventions.
The proper way to proceed with this
endeavor however, is not to flood
the market with billions of dollars
worth of hardware, most of it already
obsolete, but to limit their use to a few
centers with sincere professional in-
terest, until in well-controlled trials,
the technology proves itself econom-
ically sound, as well as clinically
superior to that which we already
have today.
Carolinas Medical Center
Charlotte, NC
doi:10.1016/j.jtcvs.2008.03.026
Simultaneous hybrid coronary
revascularization reduces
postoperative morbidity
compared with results from
conventional off-pump coronary
artery bypass
To the Editor:
This study describes a single-center experi-
ence with hybrid procedures in a small pa-
tient group of 15 hybrid patients compared
with a group of 30 matched off-pump pa-
tients. The study has 2 major shortcomings
I want to address. First, the grafts used dif-
fered between the patients because vein
grafts, bilateral internal thoracic arteries,
and radial arteries were used. The choice
of graft influences patency, as well as poten-
tial blood loss. Second, the blood loss in
their off-pump group was rather high
(.1000 mL). Third, and most important,
the quality of revascularization remains an
issue in stent implantation. Although the au-
thors tried to address this, they used the
wrong method because computed tomo-
graphic angiography does not allow for suf-
ficient detection of in-stent restenosis.
Additionally, the group sizes are too small
to allow for a determination of a trend to-
ward better 1-year graft patency; a single
stent occlusion would turn the whole trend.
Finally, off-pump coronary artery bypass
does not require occlusion of coronary ar-
teries for 8 to 12 minutes for each anastomo-
sis; by inserting a shunt, which is standard in
most centers, this occlusion can be reduced
to less than 1 minute. For these reasons,
the conclusions drawn from the results of
this study are that the hybrid procedure is
possible, even with good clinical long-term
results. The study does not provide suffi-
cient data to prove any superiority of the hy-
brid approach compared with the off-pump
coronary artery bypass procedure with com-
plete surgical revascularization.
Helmut Gulbins, MD
Department of Cardiovascular Surgery
University Hospital Eppendorf
Reply to the Editor:
A small single-center study cannot provide
definitive answers to any of the important
questions posed by Dr Gulbins. We agree
that our data do not support the conclusion
that the hybrid approach is superior to the
off-pump coronary artery bypass (OP-
CAB) procedure. An important goal of
this article is merely to provoke debate
about how innovations such as this might
be used to improve the results for surgical
revascularization.
There is no question that differences in
clinical outcomes between the 2 groups
were driven by variables other than the use
of a small thoracotomy instead of a median
sternotomy. For example, differences in the
choice of conduits undoubtedly influenced
outcome. A key advantage of the hybrid
procedure is the use of percutaneous coro-
nary intervention/stenting as a means of
avoiding the well-known shortcomings of
saphenous vein grafts that is used in more
than 95% of coronary artery bypass grafting
procedures done through a sternotomy.
Computed tomographic angiographic fol-
low-up is not adequate to detect in-stent
restenosis, but the use of coated stents ac-
cording to the entry criteria of our study
minimized the expected risk of this problem
to less than 10% in our cohort.1 The risk of
thrombosis is increased with these types of
stents, but thrombosis has a dramatic pre-
sentation that can be reliably diagnosed by
clinical means. Therefore the advantages
provided by the use of invasive angiography
instead of computed tomographic angiogra-
phy for investigating the benefits of using
stents versus the saphenous vein graft in
our cohort would have been modest.
We agree that the blood loss in the
OPCAB group was higher than has been
reported by other groups. This might have
reflected a more rigorous assessment of in-
traoperative losses, including the volume
of blood retrieved by the cell saver; weigh-
ing of sponges; and estimation of other los-
ses. It also might reflect a higher-risk
population of patients than have been en-
rolled in prior OPCAB analyses. Nonethe-
less, the blood loss and rate of transfusions
for the minimally invasive group was
clearly less than has been reported in most
other OPCAB reports.2
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